Lymphomas in individuals infected by HIV: pathologic spectrum, immunophenotypic markers, virologic association, and genetic features10,18
| . | CD20 . | BCL6 . | IRF4/MUM1 . | CD138 . | Other positive cell markers . | EBV infection (frequency) . | EBV latency . | KSHV infection . | Genetic features . |
|---|---|---|---|---|---|---|---|---|---|
| BL–plasmacytoid | Positive | Positive | Negative | Negative | CD10, MYC | Positive (60%) | I | Negative | Myc rearrangement and point mutation; TP53 point mutation |
| DLBCL, immunoblastic– plasmacytoid | Positive (may be lost) | Negative | Positive | Positive | CD10, CD30, CD5 | Positive (100%) | II/III | Negative | TP53 point mutation; Myc rearrangement (minority); RAS point mutation; BCL2 and BCL6 rearrangements |
| DLBCL, centroblastic | Positive | Positive | Negative | Negative | CD10, CD5 | Positive (25%) | — | Negative | |
| PBL of the oral cavity type | Positive (may be lost) | Negative | Positive | Positive | CD10, CD31, CD38, CD56 | Positive (70%) | 0/I | Negative | Myc rearrangement; P53 overexpression |
| Classic PEL | Negative | Negative | Positive | Positive | CD30, CD31, CD71, EMA | Positive (80-100%) | I | Positive (100%) | Complex karyotype, no recurrent translocation, Tp53 and RAS rarely mutated |
| Solid PEL | Negative | Negative | Positive | Positive | CD30, EMA | Positive (80-100%) | I | Positive (100%) | Occasional p53 positive cells |
| MCD-associated large cell lymphoma* | Positive (may be lost) | Negative | Positive | Positive | Λ light chiain, CD45 | Negative | — | Positive (100%) | Myc rearrangement, TP53 point mutation |
| HL | Negative | Negative | Positive | NR | CD15, CD30, CD40 | Positive (80-100%) | II | Negative | NR |
| . | CD20 . | BCL6 . | IRF4/MUM1 . | CD138 . | Other positive cell markers . | EBV infection (frequency) . | EBV latency . | KSHV infection . | Genetic features . |
|---|---|---|---|---|---|---|---|---|---|
| BL–plasmacytoid | Positive | Positive | Negative | Negative | CD10, MYC | Positive (60%) | I | Negative | Myc rearrangement and point mutation; TP53 point mutation |
| DLBCL, immunoblastic– plasmacytoid | Positive (may be lost) | Negative | Positive | Positive | CD10, CD30, CD5 | Positive (100%) | II/III | Negative | TP53 point mutation; Myc rearrangement (minority); RAS point mutation; BCL2 and BCL6 rearrangements |
| DLBCL, centroblastic | Positive | Positive | Negative | Negative | CD10, CD5 | Positive (25%) | — | Negative | |
| PBL of the oral cavity type | Positive (may be lost) | Negative | Positive | Positive | CD10, CD31, CD38, CD56 | Positive (70%) | 0/I | Negative | Myc rearrangement; P53 overexpression |
| Classic PEL | Negative | Negative | Positive | Positive | CD30, CD31, CD71, EMA | Positive (80-100%) | I | Positive (100%) | Complex karyotype, no recurrent translocation, Tp53 and RAS rarely mutated |
| Solid PEL | Negative | Negative | Positive | Positive | CD30, EMA | Positive (80-100%) | I | Positive (100%) | Occasional p53 positive cells |
| MCD-associated large cell lymphoma* | Positive (may be lost) | Negative | Positive | Positive | Λ light chiain, CD45 | Negative | — | Positive (100%) | Myc rearrangement, TP53 point mutation |
| HL | Negative | Negative | Positive | NR | CD15, CD30, CD40 | Positive (80-100%) | II | Negative | NR |
Other histotypes (rare) include the same lymphomas that develop in the absence of HIV infection: primary central nervous system lymphoma; lymphomas of the marginal zone; high grade B-cell lymphoma; polymorphic B-cell lymphoma (PTLD-like); plasmacytoma; peripheral T-cell lymphoma, NOS. NR, not reported. Modified and adapted from Carbone et al.18
MCD-associated large cell lymphoma should be defined on the basis of molecular clonality and not only based on the Λ phenotype.